Cyclophosphamide is one of several clinically important cancer drugs whose therapeutic efficacy is due in part to their ability to stimulate antitumor immune responses. Studying mouse models, we demonstrate that cyclophosphamide alters the composition of microbiota in the small intestine and induces the translocation of selected species of Gram-positive bacteria into secondary lymphoid organs. There, these bacteria stimulate the generation of a specific subset of "pathogenic" T helper 17 (pT H 17) cells and memory T H 1 immune responses. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram-positive bacteria showed a reduction in pT H 17 responses, and their tumors were resistant to cyclophosphamide. Adoptive transfer of pT H 17 cells partially restored the antitumor efficacy of cyclophosphamide. These results suggest that the gut microbiota help shape the anticancer immune response.
Cyclophosphamide is one of several clinically important cancer drugs whose therapeutic efficacy is due in part to their ability to stimulate antitumor immune responses. Studying mouse models, we demonstrate that cyclophosphamide alters the composition of microbiota in the small intestine and induces the translocation of selected species of Gram-positive bacteria into secondary lymphoid organs. There, these bacteria stimulate the generation of a specific subset of "pathogenic" T helper 17 (pT H 17) cells and memory T H 1 immune responses. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram-positive bacteria showed a reduction in pT H 17 responses, and their tumors were resistant to cyclophosphamide. Adoptive transfer of pT H 17 cells partially restored the antitumor efficacy of cyclophosphamide. These results suggest that the gut microbiota help shape the anticancer immune response. I t is well established that gut commensal bacteria profoundly shape mammalian immunity (1) . Intestinal dysbiosis, which constitutes a disequilibrium in the bacterial ecosystem, can lead to overrepresentation of some bacteria able to promote colon carcinogenesis by favoring chronic inflammation or local immunosuppression (2, 3) . However, the effects of microbial dysbiosis on nongastrointestinal cancers are unknown. Anticancer chemotherapeutics often cause mucositis (a debilitating mucosal barrier injury associated with bacterial translocation) and neutropenia, two complications that require treatment with antibiotics, which in turn can result in dysbiosis (4, 5) . Some antineoplastic agents mediate part of their anticancer activity by stimulating anticancer immune responses (6) . Cyclophosphamide (CTX), a prominent alkylating anticancer agent, induces immunogenic cancer cell death (7, 8) , subverts immunosuppressive T cells (9) , and promotes T H 1 and T H 17 cells controlling cancer outgrowth (10) . Here, we investigated the impact of CTX on the small intestine microbiota and its ensuing effects on the antitumor immune response.
We characterized the inflammatory status of the gut epithelial barrier 48 hours after therapy with nonmyeloablative doses of CTX or the anthracycline doxorubicin in naïve mice. Both drugs caused shortening of small intestinal villi, discontinuities of the epithelial barrier, interstitial edema, and focal accumulation of mononuclear cells in the lamina propria (LP) (Fig. 1, A and B ). After chemotherapy, the numbers of goblet cells and Paneth cells were increased in villi ( Fig. 1C ) and crypts ( Fig. 1D ), respectively. The antibac-terial enzyme lysozyme (but not the microbiocide peptide RegIIIg) was up-regulated in the duodenum of CTX-treated mice (Fig. 1E ). Orally administered fluorescein isothiocyanate (FITC)-dextran became detectable in the blood (11) 18 hours after CTX treatment, confirming an increase in intestinal permeability ( Fig. 1F ). Disruption of the intestinal barrier was accompanied by a significant translocation of commensal bacteria in >50% mice into mesenteric lymph nodes and spleens that was readily detectable 48 hours after CTX treatment, and less so after doxorubicin treatment ( Fig. 2A ). Several Gram-positive bacterial species, including Lactobacillus johnsonii (growing in >40% cases), Lactobacillus murinus, and Enterococcus hirae, could be cultured from these lymphoid organs (Fig. 2B ).
Next, we analyzed the overall composition of the gut microbiota by high-throughput 454 pyrosequencing, followed by quantitative polymerase chain reaction (QPCR) targeting the domain bacteria and specific bacterial groups. Although CTX failed to cause a major dysbiosis at early time points (24 to 48 hours, fig. S1), CTX significantly altered the microbial composition of the small intestine (but not of the caecum) in mice bearing subcutaneous cancers (namely, metastasizing B16F10 melanomas and nonmetastasizing MCA205 sarcomas) 1 week after its administration ( Fig. 2C and fig. S2 ). Consistent with previous reports on fecal samples from patients (12) , CTX induced a reduction in bacterial species of the Firmicutes phylum ( fig. S2 ) distributed within four genera and groups (Clostridium cluster XIVa, Roseburia, unclassified Lachnospiraceae, Coprococcus; table S1) in the mucosa of CTX-treated animals. QPCR was applied to determine the relative abundance (as compared to all bacteria) of targeted groups of bacteria (Lactobacillus, Enterococcus, cluster IVof the Clostridium leptum group) in the small intestine mucosa from CTXversus vehicle-treated naïve and tumor-bearing mice. In tumor bearers, the total bacterial load of the small intestine at 7 days after CTX treatment, as well as the bacterial counts of the Clostridium leptum, was not affected (Fig. 2D ). However, CTX treatment led to a reduction in the abundance of lactobacilli and enterococci ( Fig. 2D ). Together, these data reveal the capacity of CTX to provoke the selective translocation of distinct Gram-positive bacterial species followed by notable changes in the small intestinal microbiome.
Coinciding with dysbiosis 7 days after CTX administration, the frequencies of CD103 + CD11b interleukin-17 (IL-17)], and strong links between gut-residing and systemic T H 17 responses have been established in the context of autoimmune diseases affecting joints, the brain, or the pancreas (13) (14) (15) . Confirming previous work (9, 10), CTX induced the polarization of splenic CD4 + T cells toward a T H 1 [interferon-g (IFN-g)producing] and T H 17 pattern ( Fig. 3A and fig.  S3D ). This effect was specific for CTX and was not found for doxorubicin ( fig. S4 ). The gut microbiota was indispensable for driving the conversion of naïve CD4 + T cells into IL-17 producers in response to CTX. Indeed, the ex vivo IL-17 release by TCR-stimulated splenocytes increased upon CTX treatment of specific-pathogen-free (SPF) mice, yet failed to do so in germ-free (GF) mice ( S3D ). Treatment of mice with vancomycin, an antibiotic spe-cific for Gram-positive bacteria (16) , also reduced the CTX-induced T H 17 conversion ( Fig. 3A , right panel). In conventional SPF mice, the counts of lactobacilli and SFB measured in small intestine mucosa ( Fig. 2D ) positively correlated with the T H 1 and T H 17 polarization of splenocytes ( Fig. 3B and fig. S3E ), whereas that of Clostridium group IV did not ( Fig. 3B ). Together, these results point to a specific association between particular microbial components present in the gut lumen (and occasionally in lymphoid organs) and the polarity of T H responses induced by CTX treatment.
CTX increased the frequency of "pathogenic" T H 17 (pT H 17) cells, which share hallmarks of T H 1 cells (nuclear expression of the transcription factor T-bet, cytoplasmic expression of IFN-g, and surface exposure of the chemokine receptor CXCR3) and T H 17 cells (expression of RORgt, IL-17 and CCR6) (17, 18) , within the spleen ( fig.  S3F and Fig. 3C ). Again, this response depended on the gut microbiota ( Fig. 3C) . Moreover, the increase in pT H 17 cells required expression of myeloid differentiation primary response gene 88 (MyD88), which signals downstream of toll-like receptors ( fig. S6A ) and is required for the therapeutic success of anticancer chemotherapies in several tumor models (19) . In contrast, the two pattern recognition receptors, nucleotide-binding oligomerization domain-containing 1 (Nod1) and Nod2, were dispensable for the CTX-induced raise in splenic pT H 17 cells and for the tumor growthretarding effects of CTX ( fig. S6B ). These results establish the capacity of CTX to stimulate pT H 17 cells through a complex circuitry that involves intestinal bacteria and MyD88, correlating with its anticancer effects. Beyond its general effect on the frequency of pT H 17 cells, CTX induced TCRrestricted, antigen-specific immune responses against commensal bacteria ( fig. S7 ). Hence, we addressed whether Gram-positive bacterial species that translocated into secondary lymphoid organs in response to CTX ( Fig. 2A) and T H 17 cells in vitro, in the presence of bone marrow-derived dendritic cells, whereas toll-like receptor 4-activating purified bacterial lipopolysaccharide (LPS) or Escherichia coli both had a minor effect ( fig. S8 ). Moreover, orally fed L. johnsonii and E. hirae, but neither L. plantarum (a bacterium that was not detected in translocation experiments, Fig. 2B ) nor L. reuteri, facilitated the reconstitution of the pool of pT H 17 cells in the spleen of ATB-treated SPF mice (Fig.  3D) . T H 1 memory responses against L. johnsonii were consistently detected in 50% of mice receiving CTX (Fig. 3E) but not in control mice, after in vitro restimulation of CD4 + T cells with bone marrow-derived dendritic cells loaded with L. johnsonii (and to a lesser extent E. hirae, but not with other commensals or pathobionts). Taking into account that CTX-induced dysbiosis peaks at late time points (day 7), we postulate that the translocation of a specific set of Gram-positive commensal bacteria is necessary and sufficient to mediate the CTX-driven accumulation of pT H 17 cells and T H 1 bacteria-specific memory T cell responses.
Because commensal bacteria modulate intestinal and systemic immunity after CTX treatment, we further investigated the effect of antibiotics on CTX-mediated tumor growth inhibition. Longterm treatment with broad-spectrum ATB reduced the capacity of CTX to cure P815 mastocytomas established in syngenic DBA2 mice ( Fig. 4A and  fig. S9A ). Moreover, the antitumor effects mediated by CTX against MCA205 sarcomas were reduced in GF compared with SPF mice (Fig. 4B , left and middle panels). Driven by the observations that CTX mostly induced the translocation of Gram-positive bacteria and that Gram-positive bacteria correlated with splenic T H 1/T H 17 polarization, we compared the capacity of several ATB regimens: namely, vancomycin (depleting Grampositive bacteria) and colistin (depleting most Gram-negative bacteria) to interfere with the tumor growth-inhibitory effects of CTX. Vancomycin, and to a lesser extent colistin, compromised the antitumor efficacy of CTX against MCA205 sarcoma ( Fig. 4C and fig. S9B ). Using a transgenic tumor model of autochthonous lung carcinogenesis driven by oncogenic K-Ras coupled to conditional p53 deletion (20) , we confirmed the inhibitory role of vancomycin on the anticancer efficacy of a CTX-based chemotherapeutic regimen (Fig. 4D) . Vancomycin also prevented the CTX-induced accumulation of pT H 17 in the spleen (Fig. 4E ) and reduced the frequencies of tumor-infiltrating CD3 + T cells and T H 1 cells (Fig. 4F) .
Although the feces of most SPF mice treated with ATB usually were free of cultivable bacteria ( fig. S5 ), some mice occasionally experienced the outgrowth of Parabacteroides distasonis, a species reported to maintain part of the intestinal regulatory T cell repertoire and to mediate local anti-inflammatory effects (21) (22) (23) . This bacterial contamination was associated with the failure of an immunogenic chemotherapy (doxorubicin) against established MCA205 sarcomas ( fig. S10A ). Moreover, experimental recolonization of ATBsterilized mice with P. distasonis compromised the anticancer effects of doxorubicin ( fig. S10B ), demonstrating that gut microbial dysbiosis abrogates anticancer therapy. Finally, monoassociation of tumor-bearing GF mice with SFB, which promotes and spleen cells from naïve mice were cultivated in aerobic and anaerobic conditions, and colonies were enumerated (A) from each mouse treated with NaCl (Co) (n = 10 to 16 mice), CTX (n = 12 to 27 mice), or Doxo (n = 3 to 17 mice) (three to four experiments) and identified by mass spectrometry (B). In NaCl controls, attempts at bacterial identification mostly failed and yielded 67% L. murinus (not shown). Data were analyzed with the Student's t test. (C) The microbial composition (genus level) was analyzed by 454 pyrosequencing of the 16S ribosomal RNA gene from ilea and caeca of naïve mice and B16F10 tumor bearers. Principal-component analyses highlighted specific clustering of mice microbiota (each circle represents one mouse) depending on the treatment (NaCl: Co, gray circles; CTX-treated, black circles). A Monte Carlo rank test was applied to assess the significance of these clusterings. (D) QPCR analyses of various bacterial groups associated with small intestine mucosa were performed on CTX-or NaCl (Co)-treated, naïve, or MCA205 tumor-bearing mice. Absolute values were calculated for total bacteria, Lactobacilli, Enterococci, and Clostridium group IV and normalized by the dilution and weight of the sample. Standard curves were generated from serial dilutions of a known concentration of genomic DNA from each bacterial group and by plotting threshold cycles (Ct) versus bacterial quantity (colony-forming units). Points below the dotted lines were under the detection threshold. Data were analyzed with the linear model or generalized linear model. *P < 0.5, **P < 0.1, ***P < 0.001; ns, not significant. Fig. 3 . CTX-induced pT H 17 effectors and memory T H 1 responses depend on gut microbiota. (A) Splenocytes from CTX-versus NaCl-treated animals reared in germ-free (GF) or conventional specific-pathogen-free (SPF) conditions (left panel) and treated (+) or not treated (-) with ATB or vancomycin (Vanco) (right panel) were cross-linked with antibody against CD3 + CD28 for 48 hours. IL-17 was measured by enzyme-linked immunosorbent assay (ELISA). Two to three experiments containing two to nine mice per group are presented, with each symbol representing one mouse. (B) Correlations between the quantity of specific mucosal bacterial groups and the spleen T H 17 signature. Each symbol represents one mouse bearing no tumor (circles), a B16F10 melanoma (diamonds), or a MCA205 sarcoma (squares); open symbols denote NaCl-treated mice and filled symbols indicate CTX-treated animals. (C) Intracellular analyses of splenocytes harvested from non-tumor-bearing mice after 7 days of either NaCl or CTX treatment, under a regimen of ATB or with water as control. Means T SEM of percentages of IFN-g + T H 17 cells, T-bet + cells among RORgt + CD4 + T cells, and CXCR3 + cells among CCR6 + CD4 + T cells in two to eight independent experiments, with each circle representing one mouse. (D) Intracellular staining of total splenocytes harvested 7 days after CTX treatment from naïve mice orally reconstituted with the indicated bacterial species after ATB treatment. (E) Seven days after CTX or NaCl (Co) treatment, splenic CD4 + T cells were restimulated ex vivo with bone-marrow dendritic cells loaded with decreasing amounts of bacteria for 24 hours. IFN-g release, monitored by ELISA, is shown. The numbers of responder mice (based on the NaCl baseline threshold) out of the total number of mice tested is indicated (n). Statistical comparisons were based on the paired t test. Data were analyzed with either beta regression or linear model and correlation analyses from modified Kendall tau. *P < 0.05, ***P < 0.001; ns, not significant.
T H 17 cell differentiation in the LP (1, 13, 14) , also had a detrimental impact on the tumor growthinhibitory effect of CTX (Fig. 4B, right panel) .
The aforementioned results highlight the association between specific CTX-induced alterations in gut microbiota, the accumulation of pT H 17 cells in the spleen, and the success of chemotherapy. To establish a direct causal link between these phenomena, we adoptively transferred T H 17 Fig. 4 . Vancomycin blunts CTX-induced pT H 17 differentiation, which is mandatory for the tumoricidal activity of chemotherapy. (A) After a 3-week-long pretreatment with broadspectrum ATB, DBA2 mice were inoculated with P815 mastocytomas (day 0) and treated at day 6 with CTX, and tumor growth was monitored. Tumor growth kinetics are shown in fig. S9A , and percentages of tumor-free mice at the time mice were killed are depicted for two experiments of 11 to 14 mice per group. (B) MCA205 sarcomas were inoculated at day 0 in specific-pathogen-free (SPF) or germ-free (GF) mice that were optionally mono-associated with segmented filamentous bacteria (SFB), treated with CTX (arrow), and monitored for growth kinetics (means T SEM). One representative experiment (n = 5 to 8 mice per group) out of two or three is shown for GF mice and two pooled experiments (n = 14 mice per group) for SPF mice. (C) After a 3-week conditioning with vancomycin or colistin, C57BL/6 mice were inoculated with MCA205 sarcomas (day 0) and treated at day 12 to 15 with CTX (arrow), and tumor growth was monitored. Pooled data (n = 15 to 20 mice per group) from two independent experiments are shown for colistin treatment and one representative experiment (n = 6 mice per group) for vancomycin treatment. (D) Eight-week-old KP (KrasLSL-G12D/WT; p53 Flox/Flox ) mice received an adenovirus expressing the Cre recombinase (AdCre) by intranasal instillation to initiate lung adenocarcinoma (day 0). Vancomycin was started for a subgroup of mice (Chemo + Vanco) on day 77 after AdCre treatment. One week after the start of vancomycin, CTX-based chemotherapy was applied intraperitoneally to mice that received only chemotherapy (Chemo) or that received in parallel vancomycin (Chemo + Vanco). Mice received chemotherapy on days 84, 91, and 98. A control group was left untreated (Co). Data show the evolution of total lung tumor volumes (mean T SEM) assessed by noninvasive imaging between days 73 and 100 in 6 to 12 mice per group. (E) As in Fig. 3C , we determined the number of pT H 17 cells in spleens from untreated or vancomycin-treated mice bearing established (15 to 17 days) MCA205 tumors, 7 days after CTX treatment. Each symbol represents one mouse from two pooled experiments. (F) Flow cytometric analyses of CD3 + and CD4 + IFN-g + T cells were performed by gating on CD45 + live tumor-infiltrating lymphocytes extracted from day 18 established MCA205 tumors (8 days after CTX treatment) in water-or vancomycin-treated mice. Each symbol represents one mouse from up to four pooled experiments. (G) MCA205 tumors established in wild-type mice pretreated for 3 weeks with water or vancomycin were injected with CTX (arrow), and tumor growth was monitored. At day 7 after CTX treatment, 3 million ex vivo generated T H 17 or pT H 17 CD4 + T cells were injected intravenously. Up to three experiments with 2 to 10 mice per group were pooled. Data were analyzed with either the t test, linear model, or generalized linear model. *P < 0.5, **P < 0.1, ***P < 0.001; ns, not significant.
www.sciencemag.org SCIENCE VOL 342 22 NOVEMBER 2013 or pT H 17 populations into vancomycin-treated mice and evaluated their capacity to reestablish the CTX-mediated tumor growth retardation. Ex vivo propagated pT H 17 exhibited a pattern of gene expression similar to that expressed by CTX-induced splenic CD4 + T cells in vivo (fig. S11). Only pT H 17, but not T H 17 cells, could rescue the negative impact of vancomycin on the CTXmediated therapeutic effect (Fig. 4G) . These results emphasize the importance of pT H 17 cells for CTX-mediated anticancer immune responses.
Although much of the detailed molecular mechanisms governing the complex interplay between epithelial cells, gut microbiota, and intestinal immunity remain to be deciphered, the present study unveils the unsuspected impact of the intestinal flora on chemotherapy-elicited anticancer immune responses. Our data underscore new risks associated with antibiotic medication during cancer treatments, as well as the potential therapeutic utility of manipulating the gut microbiota.
